Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Olpasiran (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 19 Apr 2023 Status changed from active, no longer recruiting to completed.
- 21 Nov 2022 Planned End Date changed from 29 Apr 2023 to 19 Apr 2023.
- 21 Nov 2022 Planned primary completion date changed from 29 Apr 2023 to 19 Apr 2023.